يعرض 121 - 140 نتائج من 74,994 نتيجة بحث عن '(((( 50 ms decrease ) OR ( a non decrease ))) OR ( 5 ((nn decrease) OR (a decrease)) ))', وقت الاستعلام: 1.15s تنقيح النتائج
  1. 121

    Image_3_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.jpeg حسب Casey E. Vantucci (10528263)

    منشور في 2022
    "…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …"
  2. 122

    Image_6_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.jpeg حسب Casey E. Vantucci (10528263)

    منشور في 2022
    "…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …"
  3. 123

    Table_2_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.docx حسب Casey E. Vantucci (10528263)

    منشور في 2022
    "…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …"
  4. 124

    Image_1_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.jpeg حسب Casey E. Vantucci (10528263)

    منشور في 2022
    "…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …"
  5. 125
  6. 126
  7. 127
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc حسب Lei Wang (6656)

    منشور في 2025
    "…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"
  15. 135
  16. 136
  17. 137

    Data_Sheet_1_Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity.d... حسب Chantal C. Clark (10684632)

    منشور في 2021
    "…</p><p>Conclusion: We observed an association between the use of preexisting thromboprophylaxis and a decreased risk of TE during COVID-19. This suggests that these therapies are beneficial for coping with COVID-19 associated hypercoagulability. …"
  18. 138
  19. 139

    Decrease in accelerometer assessed physical activity during the first-year post-myocardial infarction: a prospective cohort study حسب Amanda Lönn (11583010)

    منشور في 2024
    "…Patients included during covid-19 restrictions and younger patients had a higher level of moderate-intensity physical activity compared to patients included during non-pandemic restrictions and older patients. …"
  20. 140